At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Post-Mkt 07-16 16:50:00 EDT
371.58
+13.26
+3.70%
盘后371.19
-0.39-0.10%
16:41 EDT
High372.14Low357.74Vol2.28M
Open358.25D1 Closing358.32Amplitude4.02%
Mkt Cap200.09BTradable Cap199.54BTotal Shares538.48M
T/O840.98MT/O Rate0.42%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Amgen Inc Stock (AMGN) Closed Up by 3.70% on Jul 16: Drivers Behind the Movement
TradingKey  ·  35 minutes ago
Amgen Inc Stock (AMGN) Closed Up by 3.70% on Jul 16: Drivers Behind the Movement
Gyre Therapeutics Adds CSO Yue Xiong, Max Kirkby, Claire Weston to Board Effective Aug. 1
Reuters  ·  43 minutes ago
Gyre Therapeutics Adds CSO Yue Xiong, Max Kirkby, Claire Weston to Board Effective Aug. 1
Movement Alert｜Amgen Rises 3.03% in Regular Trading, Multiple Investment Banks Raise Target Prices Amid Sector Strength
Market Focus  ·  01:53
Movement Alert｜Amgen Rises 3.03% in Regular Trading, Multiple Investment Banks Raise Target Prices Amid Sector Strength
Amgen Advances Obesity Pipeline With Fresh Data on AMG 133 Injection Formats
TIPRANKS  ·  00:30
Amgen Advances Obesity Pipeline With Fresh Data on AMG 133 Injection Formats
Amgen’s Rocatinlimab Eczema Trial Termination Jolts Investor Expectations
TIPRANKS  ·  00:30
Amgen’s Rocatinlimab Eczema Trial Termination Jolts Investor Expectations
Merck Gets US FDA Nod for First-in-its-class Oral Cholesterol Drug
Reuters  ·  07-16 20:04
Merck Gets US FDA Nod for First-in-its-class Oral Cholesterol Drug
Citi Sticks to Its Hold Rating for Amgen (AMGN)
TIPRANKS  ·  07-16 04:37
Citi Sticks to Its Hold Rating for Amgen (AMGN)
Amgen Inc. Stock Outperforms Competitors Despite Losses on the Day
Dow Jones  ·  07-15 04:34
Amgen Inc. Stock Outperforms Competitors Despite Losses on the Day
Sino Biopharmaceutical Stock Slips 1.0% in Hong Kong, Underperforms Competitors
Dow Jones  ·  07-14 16:33
Sino Biopharmaceutical Stock Slips 1.0% in Hong Kong, Underperforms Competitors
BofA Securities Adjusts Amgen Price Target to $312 From $307
MT Newswires Live  ·  07-13
BofA Securities Adjusts Amgen Price Target to $312 From $307
UBS Adjusts Price Target on Amgen to $420 From $400, Maintains Buy Rating
MT Newswires Live  ·  07-13
UBS Adjusts Price Target on Amgen to $420 From $400, Maintains Buy Rating
Amgen Inc : UBS Raises Target Price to $420 from $400
THOMSON REUTERS  ·  07-13
Amgen Inc : UBS Raises Target Price to $420 from $400
Cue Biopharma Names Dominic Borie Chief Medical Officer, Head of R&D
Reuters  ·  07-13
Cue Biopharma Names Dominic Borie Chief Medical Officer, Head of R&D
Amgen is Maintained at Neutral by Guggenheim
Dow Jones  ·  07-13
Amgen is Maintained at Neutral by Guggenheim
BMO Capital Sticks to Their Buy Rating for Amgen (AMGN)
TIPRANKS  ·  07-13
BMO Capital Sticks to Their Buy Rating for Amgen (AMGN)
Sino Biopharmaceutical Stock Advances 3.8% in Hong Kong, Outperforms Competitors
Dow Jones  ·  07-10
Sino Biopharmaceutical Stock Advances 3.8% in Hong Kong, Outperforms Competitors
Amgen Inc. Stock Outperforms Competitors Despite Losses on the Day
Dow Jones  ·  07-10
Amgen Inc. Stock Outperforms Competitors Despite Losses on the Day
Sino Biopharmaceutical Stock Rises 3.7% in Hong Kong, Outperforms Competitors
Dow Jones  ·  07-09
Sino Biopharmaceutical Stock Rises 3.7% in Hong Kong, Outperforms Competitors
Amgen Targets Carbon Neutrality by 2027 for Owned, Operated Facilities and Operations
Reuters  ·  07-09
Amgen Targets Carbon Neutrality by 2027 for Owned, Operated Facilities and Operations
Amgen is Maintained at Equal-weight by Morgan Stanley
Dow Jones  ·  07-09
Amgen is Maintained at Equal-weight by Morgan Stanley

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--